Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities.

Bhathika Perera¹, Charles Steward², Ken Courtenay¹, Timothy Andrews³, Rohit Shankar⁴

¹Barnet, Enfield and Haringey Mental Health NHS Trust, London, UK.

²Congenica Ltd, Cambridge, UK.

³Oxford Health NHS Foundation Trust, Oxford, UK.

⁴Peninsula School of Medicine, University of Plymouth, UK; and Cornwall Partnership NHS Foundation Trust, Truro, UK.

PubMed PMC DOI PDF

Abstract

There is growing evidence for the use of pharmacogenomics in psychotropic prescribing. People with intellectual disabilities are disproportionately prescribed psychotropics and are at risk of polypharmacy. There is an urgent need for safeguards to prevent psychotropic overprescribing but it is equally crucial that this population is not left behind in such exciting initiatives. Understanding how g…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.